At the release of the financial results for the fiscal third quarter ending 31 January 2020 KalVista Pharmaceuticals, Inc. CEO Andrew Crockett said the ‘work to bring multiple best-in-class oral therapies to patients with HAE is advancing well’:
“First, we look forward to delivering data in the second quarter of this year from our Phase 2 clinical trial with KVD900, our on-demand therapy for HAE attacks. We believe KVD900 has the potential to offer patients an attractive option for control of their disease through a fast-acting tablet that can be taken at the earliest stages of an incipient attack. Second, we continue to make progress in our optimization of KVD824 as a potential oral prophylactic treatment. We still plan to initiate a Phase 2 trial of KVD824 for prophylaxis of HAE attacks in the second half of the year.”
(Source: KalVista)
